Ketamine Does Not Increase Pulmonary Vascular Resistance in Children with Pulmonary Hypertension Undergoing Sevoflurane Anesthesia and Spontaneous Ventilation

BACKGROUND:The use of ketamine in children with increased pulmonary vascular resistance is controversial. In this prospective, open label study, we evaluated the hemodynamic responses to ketamine in children with pulmonary hypertension (mean pulmonary artery pressure >25 mm Hg). METHODS:Children aged 3 mo to 18 yr with pulmonary hypertension, who were scheduled for cardiac catheterization with general anesthesia, were studied. Patients were anesthetized with sevoflurane (1 minimum alveolar anesthetic concentration [MAC]) in air while breathing spontaneously via a facemask. After baseline catheterization measurements, sevoflurane was reduced (0.5 MAC) and ketamine (2 mg/kg IV over 5 min) was administered, followed by a ketamine infusion (10 &mgr;g · kg−1 · min−1). Catheterization measurements were repeated at 5, 10, and 15 min after completion of ketamine load. Data at various time points were compared (ANOVA, P < 0.05). RESULTS:Fifteen patients (age 147, 108 mo; median, interquartile range) were studied. Diagnoses included idiopathic pulmonary arterial hypertension (5), congenital heart disease (9), and diaphragmatic hernia (1). At baseline, median (interquartile range) baseline pulmonary vascular resistance index was 11.3 (8.2) Wood units; 33% of patients had suprasystemic mean pulmonary artery pressures. Heart rate (99, 94 bpm; P = 0.016) and Pao2 (95, 104 mm Hg; P = 007) changed after ketamine administration (baseline, 15 min after ketamine; P value). There were no significant differences in mean systemic arterial blood pressure, mean pulmonary artery pressure, systemic or pulmonary vascular resistance index, cardiac index, arterial pH, or Paco2. CONCLUSIONS:In the presence of sevoflurane, ketamine did not increase pulmonary vascular resistance in spontaneously breathing children with severe pulmonary hypertension.

[1]  A. McEwan,et al.  Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. , 2007, British journal of anaesthesia.

[2]  R. Friesen,et al.  Perioperative Complications in Children with Pulmonary Hypertension Undergoing Noncardiac Surgery or Cardiac Catheterization , 2007, Anesthesia and analgesia.

[3]  R. Tulloh Management and therapeutic options in pediatric pulmonary hypertension , 2006, Expert review of cardiovascular therapy.

[4]  J. Bovill Intravenous Anesthesia for the Patient with Left Ventricular Dysfunction , 2006, Seminars in cardiothoracic and vascular anesthesia.

[5]  J. Loscalzo,et al.  Pulmonary arterial hypertension. , 2004, Annals of medicine.

[6]  M. Serpell,et al.  Anaesthesia for cholecystectomy in two non‐parturients with Eisenmenger's syndrome , 2004, Acta anaesthesiologica Scandinavica.

[7]  L. Rubin,et al.  Introduction: New Insights Into a Challenging Disease A Review of the Third World Symposium on Pulmonary Arterial Hypertension , 2004 .

[8]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[9]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[10]  A. Heller,et al.  A fine balance--one-lung ventilation in a patient with Eisenmenger syndrome. , 2004, British journal of anaesthesia.

[11]  D. Langleben,et al.  Pulmonary Arterial Hypertension: Pathophysiology and Anesthetic Approach , 2003, Anesthesiology.

[12]  P. Neema,et al.  Anesthetic management for a hypertensive patent ductus arteriosus (PDA) closure in a patient with surgically uncorrectable long-segment right pulmonary artery hypoplasia and a ventricular septal defect. , 2003, Journal of cardiothoracic and vascular anesthesia.

[13]  U. Ozbek,et al.  Which anesthetic agent alters the hemodynamic status during pediatric catheterization? Comparison of propofol versus ketamine. , 2003, Journal of cardiothoracic and vascular anesthesia.

[14]  H. Aken,et al.  Management of Pulmonary Hypertension: Physiological and Pharmacological Considerations for Anesthesiologists , 2003, Anesthesia and analgesia.

[15]  C. Fraser,et al.  Pulmonary-to-Systemic Blood Flow Ratio Effects of Sevoflurane, Isoflurane, Halothane, and Fentanyl/Midazolam with 100% Oxygen in Children with Congenital Heart Disease , 2002, Anesthesia and analgesia.

[16]  K. S. Lim,et al.  Severe Pulmonary Hypertension in a Patient with Bronchiectasis Complicated by Cor Pulmonale and a Right-to-left Shunt Presenting for Surgery , 2002, Anaesthesia and intensive care.

[17]  B. Milne,et al.  Ketamine anesthesia for pericardial window in a patient with pericardial tamponade and severe COPD , 2002, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[18]  T. Akata,et al.  Mechanisms of Direct Inhibitory Action of Isoflurane on Vascular Smooth Muscle of Mesenteric Resistance Arteries , 2001, Anesthesiology.

[19]  T. Akata,et al.  Mechanisms of Direct Inhibitory Action of Ketamine on Vascular Smooth Muscle in Mesenteric Resistance Arteries , 2001, Anesthesiology.

[20]  S. Tanaka,et al.  Inhibitory Effects of Etomidate and Ketamine on Endothelium-dependent Relaxation in Canine Pulmonary Artery , 2001, Anesthesiology.

[21]  B. Nossaman,et al.  Analysis of ketamine responses in the pulmonary vascular bed of the cat , 2000, Critical care medicine.

[22]  T. Jones,et al.  The hemodynamic effects of propofol in children with congenital heart disease. , 1999, Anesthesia and analgesia.

[23]  R. Friesen,et al.  Changes in carbon dioxide tension and oxygen saturation during deep sedation for paediatric cardiac catheterization , 1996, Paediatric anaesthesia.

[24]  B. Lyons,et al.  The anaesthetic management of the child with Eisenmenger’s syndrome , 1995, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[25]  H. Toda,et al.  Modification of Endothelium-Dependent Relaxation by Propofol, Ketamine, and Midazolam , 1995, Anesthesia and analgesia.

[26]  K. Miyasaka,et al.  Vasodilatory Effects of Ketamine on Pulmonary Arteries in Rats with Chronic Hypoxic Pulmoanry Hypertension , 1995, Anesthesia and analgesia.

[27]  T. Lee,et al.  Vasoactive effects of ketamine on isolated rabbit pulmonary arteries. , 1995, Chest.

[28]  D. Uncles,et al.  Direct Effects of Intravenous Anesthetics on Pulmonary Vascular Resistance in the Isolated Rat Lung , 1994, Anesthesia and analgesia.

[29]  R. Laravuso,et al.  Mechanisms of the Inhibitory Effect of Ketamine on Guinea Pig Isolated Main Pulmonary Artery , 1994, Anesthesia and analgesia.

[30]  W. Berman,et al.  Hemodynamic effects of ketamine in children undergoing cardiac catheterization , 1990, Pediatric Cardiology.

[31]  F. Burrows,et al.  Pulmonary hypertension in children: perioperative management , 1986, Canadian Anaesthetists' Society journal.

[32]  J. Stevenson,et al.  Hemodynamic Effects of Ketamine in Children with Congenital Heart Disease , 1984, Anesthesia and analgesia.

[33]  P. Hickey,et al.  Pulmonary and Systemic Hemodynamic Responses to Ketamine in Infants with Normal and Elevated Pulmonary Vascular Resistance , 1984, Anesthesiology.

[34]  G. Y. Gaines,et al.  One‐Lung Anesthesia—A Comparison of Pulmonary Gas Exchange during Anesthesia with Ketamine or Enflurane , 1984, Anesthesia and analgesia.

[35]  P. White,et al.  Ketamine--its pharmacology and therapeutic uses. , 1982, Anesthesiology.

[36]  P. Skovsted,et al.  The cardiovascular effects of ketamine used for induction of anaesthesia in patients with valvular heart disease , 1979, Canadian Anaesthetists' Society journal.

[37]  W. Tweed,et al.  Circulatory Responses to Ketamine Anesthesia , 1972, Anesthesiology.

[38]  R. Wolfe,et al.  Hemodynamic effects of ketamine, hypoxia and hyperoxia in children with surgically treated congenital heart disease residing greater than or equal to 1,200 meters above sea level. , 1991, The American journal of cardiology.

[39]  R. Wolfe,et al.  Hemodynamic effects of ketamine, hypoxia and hyperoxia in children with surgically treated congenital heart disease residing ≥ 1,200 meters above sea level , 1991 .